Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 2/20 | 0.85 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.85 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.85 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361006 | 0.92 | EP300 (1.00) | EP300KAT2BKAT8AXLIDO1 | |
| SCHEMBL30152344 | 0.92 | EP300 (1.00) | EP300KAT2BKAT8AXLIDO1 | |
| SCHEMBL5894746 | 0.84 | AXL (0.72) | EP300KAT2BKAT8AXLKDM4E | |
| SCHEMBL31339925 | 0.75 | GAA (0.59) | EP300KAT2BKAT8AXLIDO1 | |
| SCHEMBL14589052 | 0.75 | AXL (0.55) | EP300KAT2BKAT8AXLIDO1 | |
| SCHEMBL619424 | 0.75 | GAA (0.59) | EP300KAT2BKAT8AXLIDO1 | |
| SCHEMBL4021511 | 0.75 | AXL (0.85) | EP300KAT2BKAT8AXLIDO1 | |
| SCHEMBL19055162 | 0.75 | AXL (0.55) | EP300KAT2BKAT8AXLKDM4E | |
| SCHEMBL1350740 | 0.75 | AXL (0.55) | EP300KAT2BKAT8AXLIDO1 | |
| SCHEMBL21917158 | 0.75 | AXL (0.60) | EP300KAT2BKAT8AXLIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2020132045-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEUROPROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020081923-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-2285805-B1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| EP-2285805-B1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2009130487-A1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | EP300 70/4885KAT2B 1199/4885KAT8 1003/4885 |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | BRAF, NRAS, ARAF | EP300 1392/4885KAT2B 3579/4885KAT8 3066/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | EP300 932/4885KAT2B 2167/4885KAT8 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.